Novartis agrees to acquire UK biotech Myricx Bio for up to $1.5 billion.
Swiss pharmaceutical company Novartis announced an agreement to acquire UK-based biotechnology firm Myricx Bio. The deal is valued at up to $1.5 billion and is expected to close in the second half of 2026.
3
Divergence score
2 outlets covered it, splitting into 2 framing camps across 2 bias groups.
2 camps
2 bias groups
Market signalBETA
The spectrum · how 2 outlets placed this story
LeftCenterRight
Financial Times
Reuters
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
Widest split · the two outlets furthest apart, and who published first
First to report
- Reutersfirst
- Financial Times+5.4 h
By each outlet's earliest publish time in this story. Feeds that index slowly can appear later than they printed.
The split, in one line
Both outlets report identical deal terms; Financial Times leads with the headline figure while Reuters clarifies the up to contingency structure.
How each outlet covered it
Lightly covered so far
Too few outlets to map a left-right split. Here is each take as it stands.
Sparse coverage · 2 outlets
“Novartis to acquire UK-based Myricx Bio for up to $1.5 billion”
“Novartis to buy UK biotech Myricx Bio in $1.5bn deal”
3 tracked claims across 2 outlets
Fact ledger
All3Claimed1Corroborated2
1/2
Claimed
The deal is expected to close in the second half of 2026.
Corroborated
Disputed
2 more tracked claimsSign up free to see the full ledger